Table 2.
Univariate and multivariate analysis of overall survival in women
| Univariate analysis
|
Multivariate analysis
|
|||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Year of diagnosis | ||||
| 2004–2008 | Reference | |||
| 2009–2013 | 0.7 (0.43–1.13) | 0.14 | ||
| Age at diagnosis, years | ||||
| 0–54 | Reference | |||
| 55–64 | 0.71 (0.34–1.45) | 0.35 | ||
| 65–74 | 1.1 (0.55–2.18) | 0.79 | ||
| 75–84 | 1.45 (0.74–2.84) | 0.28 | ||
| 85+ | 1.76 (0.84–3.68) | 0.14 | ||
| Race | ||||
| White | Reference | Reference | ||
| Black | 1.68 (1.07–2.62) | 0.02* | 1.73 (1.01–2.96) | 0.04* |
| Other | 1 (0.43–2.35) | 1 | 0.83 (0.33–2.1) | 0.69 |
| Marital status | ||||
| Not married | Reference | Reference | ||
| Married | 0.62 (0.38–1) | 0.049* | 0.72 (0.43–1.22) | 0.22 |
| Unknown | 1.77 (0.8–3.91) | 0.16 | 1.05 (0.39–2.77) | 0.93 |
| Grade | ||||
| I and II | Reference | Reference | ||
| III | 1.86 (1.11–3.11) | 0.02* | 1.59 (0.9–2.83) | 0.11 |
| IV | 0.94 (0.4–2.2) | 0.89 | 1.02 (0.41–2.54) | 0.97 |
| Unknown | 2.11 (1.13–3.96) | 0.02* | 1.7 (0.81–3.58) | 0.16 |
| Tumor size, cm | ||||
| ≤2 | Reference | |||
| >2 and ≤5 | 1.21 (0.57–2.56) | 0.62 | ||
| >5 | 0.92 (0.34–2.55) | 0.88 | ||
| Unknown | 1.15 (0.58–2.27) | 0.7 | ||
| Positive-node status | ||||
| 0 | Reference | |||
| 1–3 | 1.29 (0.61–2.7) | 0.51 | ||
| >3 | – | – | ||
| Unknown | 1.26 (0.72–2.23) | 0.42 | ||
| AJCC stage | ||||
| I | Reference | Reference | ||
| II | 0.44 (0.25–0.77) | <0.001* | 0.77 (0.1–5.89) | 0.8 |
| III and IV | 0.61 (0.35–1.05) | 0.08 | 1.06 (0.18–6.27) | 0.94 |
| Unknown | 1.2 (0.75–1.92) | 0.44 | 0.6 (0.08–4.32) | 0.62 |
| pT stage | ||||
| T0 and T1 | Reference | Reference | ||
| T2 | 1 (0.5–2.04) | 0.99 | 1.43 (0.22–9.1) | 0.71 |
| T3 | 2.09 (1.17–3.71) | 0.01* | 1.35 (0.26–7.08) | 0.73 |
| T4 and TX | 2.04 (1.09–3.81) | 0.03* | 1.35 (0.25–7.23) | 0.73 |
| pN stage | ||||
| N0 | Reference | Reference | ||
| N1 | 1.07 (0.56–2.04) | 0.83 | 0.78 (0.32–1.93) | 0.6 |
| N2 | 2.24 (1.13–4.43) | 0.02* | 1.33 (0.61–2.91) | 0.48 |
| NX | 1.31 (0.6–2.87) | 0.5 | 0.89 (0.21–3.83) | 0.88 |
| pM stage | ||||
| M0 | Reference | Reference | ||
| M1 | 4.2 (2.4–7.37) | <0.001* | 2.3 (1.07–4.93) | 0.03* |
| MX | 1.31 (0.48–3.6) | 0.6 | 1.97 (0.36–10.9) | 0.44 |
| Surgery | ||||
| No | Reference | Reference | ||
| Yes | 0.49 (0.32–0.75) | 0.001* | 0.56 (0.33–0.93) | 0.03* |
| Radiation | ||||
| Yes | Reference | |||
| No | 1.17 (0.76–1.81) | 0.47 | ||
| Histological type | ||||
| SCC, NOS | Reference | |||
| TCC, NOS | 1.05 (0.61–1.83) | 0.85 | ||
| Ac, NOS | 1.34 (0.8–2.27) | 0.27 | ||
Note:
*
P<0.05.
Abbreviations: AJCC, American Joint Committee on Cancer; SCC, squamous cell carcinoma; TCC, transitional cell carcinoma; Ac, adenocarcinoma; NOS, not otherwise specified.